Finanical Statements
Glaxo Smith Kline (BIOC.CA) Reports 6 Months Consolidated Results
Published at 13 August 2026 at 11:02Glaxo Smith KlineRelated stock:Glaxo Smith Kline stockAll Glaxo Smith Kline disclosures
Disclosure summary
Company Name : Glaxo Smith Kline
ISIN Code : EGS38171C012
Currency : EGP
F/S Consolidated Period : From 01/01/2026 To 30/06/2026
Net Profit : 43,898,726
F/S Consolidated Period : From 01/01/2025 To 30/06/2025
Net Comparative Profit : 65,052,473
Audit Status : Reviewed
Comment : Taking into consideration minority rights
Source : Glaxo Smith Kline
The Financial Statements in Arabic (6,075 KB)
The Financial Statements in English (6,678 KB)
ISIN Code : EGS38171C012
Currency : EGP
F/S Consolidated Period : From 01/01/2026 To 30/06/2026
Net Profit : 43,898,726
F/S Consolidated Period : From 01/01/2025 To 30/06/2025
Net Comparative Profit : 65,052,473
Audit Status : Reviewed
Comment : Taking into consideration minority rights
Source : Glaxo Smith Kline
The Financial Statements in Arabic (6,075 KB)
The Financial Statements in English (6,678 KB)